ArticleDiabetes technology & therapeutics2012
Use of continuous glucose monitoring as an outcome measure in clinical trials.
Article in Diabetes technology & therapeutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07155993 (FastForward), which is not on this map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
FastForward: A Prospective Analysis of Long-term Fasting and Subsequent Food Reintroduction in Humans
Who cites it
27 citing papers in PubMed, 59 citations in OpenAlex.
- Associations between HbADiabetic medicine : a journal of the British Diabetic Association · 2019Trial
- Acute effects of breaking up prolonged sitting on fatigue and cognition: a pilot study.BMJ open · 2016Trial
- A randomized trial of a home system to reduce nocturnal hypoglycemia in type 1 diabetes.Diabetes care · 2014Trial
- Association of time in range with cognitive impairment in middle-aged type 2 diabetic patients.BMC endocrine disorders · 2024Article
- [The impact of remote monitoring of glycemia self-control on carbohydrate metabolism and quality of life in patients with type 1 diabetes mellitus].Problemy endokrinologii · 2024Article
- Sociodemographic and Clinical Determinants on Health-Related Quality of Life in Emerging Andalusian Adults with Type 1 Diabetes: A Cross-Sectional Study.Journal of clinical medicine · 2023Article
- Attachment in close relationships and glycemic outcomes in children with type 1 diabetes.Child and adolescent psychiatry and mental health · 2023Article
- Investigating the value of glucodensity analysis of continuous glucose monitoring data in type 1 diabetes: an exploratory analysis.Frontiers in clinical diabetes and healthcare · 2023Article
- Time in range assessed by capillary blood glucose in relation to insulin sensitivity and β-cell function in patients with type 2 diabetes mellitus: A cross-sectional study in China.Journal of diabetes investigation · 2022Article
- Association of time in range with postoperative wound healing in patients with diabetic foot ulcers.International wound journal · 2022Article
- Impact of time in range during hospitalization on clinical outcomes in diabetic patients with toe amputation: a propensity score matching analysis.BMC surgery · 2022Article
- Individual Postprandial Glycemic Responses to Diet in n-of-1 Trials: Westlake N-of-1 Trials for Macronutrient Intake (WE-MACNUTR).The Journal of nutrition · 2021Article
- Fasting and postprandial plasma glucose contribution to glycated haemoglobin and time in range in people with type 2 diabetes on basal and bolus insulin therapy: Results from a pooled analysis of insulin lispro clinical trials.Diabetes, obesity & metabolism · 2021Article
- Functional data analysis and prediction tools for continuous glucose-monitoring studies.Journal of clinical and translational science · 2020Article
- The impact of type 1 diabetes on young adults' health-related quality of life.Health and quality of life outcomes · 2020Article
- Differences for Percentage Times in Glycemic Range Between Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG Dataset.Diabetes technology & therapeutics · 2020Article
- The Correlation between Time in Range and Diabetic Microvascular Complications Utilizing Information Management Platform.International journal of endocrinology · 2020Article
- Connecting the Dots: Validation of Time in Range Metrics With Microvascular Outcomes.Diabetes care · 2019Article
- Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials.Diabetes care · 2019Article
- The Association of Biochemical Hypoglycemia with the Subsequent Risk of a Severe Hypoglycemic Event: Analysis of the DCCT Data Set.Diabetes technology & therapeutics · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough developed to be a management tool for individuals with diabetes, continuous glucose monitoring (CGM) also has potential value for the assessment of outcomes in clinical studies. We evaluated using CGM as such an outcome measure. RESEARCH DESIGN AND
methodsData were analyzed from six previously completed inpatient studies in which both CGM (Freestyle Navigator™ [Abbott Diabetes Care, Alameda, CA] or Guardian(®) [Medtronic, Northridge, CA]) and reference glucose measurements were available. The analyses included 97 days of data from 93 participants with type 1 diabetes (age range, 5-57 years; mean, 18 ± 12 years).
resultsMean glucose levels per day were similar for the CGM and reference measurements (median, 148 mg/dL vs. 143 mg/dL, respectively; P = 0.92), and the correlation of the two was high (r = 0.89). Similarly, most glycemia metrics showed no significant differences comparing CGM and reference values, except that the nadir glucose tended to be slightly lower and peak glucose slightly higher with reference measurements than CGM measurements (respective median, 59 mg/dL vs. 66 mg/dL [P = 0.05] and 262 mg/dL vs. 257 mg/dL [P = 0.003]) and glucose variability as measured with the coefficient of variation was slightly lower with CGM than reference measurements (respective median, 31% vs. 35%; P<0.001).
conclusionsA reasonably high degree of concordance exists when comparing outcomes based on CGM measurements with outcomes based on reference blood glucose measurements. CGM inaccuracy and underestimation of the extremes of hyperglycemia and hypoglycemia can be accounted for in a clinical trial's study design. Thus, in appropriate settings, CGM can be a very meaningful and feasible outcome measure for clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.